Patent Win For Sofosbuvir In India But "Tortured" Ruling Faces Appeal
Executive Summary
India has approved a Gilead Sciences Inc. patent that claims the active metabolites of sofosbuvir amid allegations by opponents of "external pressures" on the patent office and that the decision "weakens" Section 3(d) of India's patent regulation.